Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. (Q44187537)
Jump to navigation
Jump to search
scientific article published on 4 June 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. |
scientific article published on 4 June 2013 |
Statements
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial (English)
Camilla Thellenberg Karlsson
Aude Fléchon
Iwona Skoneczna
Francisco Orlandi
Gwenaelle Gravis
Vsevolod Matveev
Sevil Bavbek
Thierry Gil
Osvaldo Arén
Oleg Karyakin
Alison Birtle
Emmanuelle Magherini
Laurence Hatteville
Daniel Petrylak
Bertrand Tombal
Mark Rosenthal
VENICE investigators